Spread of nasopharyngeal carcinoma is reduced by bevacizumab, according to phase 2 trial results
Friday, December 16, 2011 - 14:00
in Health & Medicine
The trial conducted by the Radiation Therapy Oncology Group (RTOG) shows the feasibility to deliver bevacizumab to the current chemoradiation standard without any apparent increased adverse side effects.